866-997-4948(US-Canada Toll Free)

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 114 Pages


Global Markets Directs, \'Gastrointestinal Stromal Tumor (GIST) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST). 

Gastrointestinal Stromal Tumor (GIST) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Gastrointestinal Stromal Tumor (GIST).
  • A review of the Gastrointestinal Stromal Tumor (GIST) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Gastrointestinal Stromal Tumor (GIST) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumor (GIST) Overview
Therapeutics Development
An Overview of Pipeline Products for Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor (GIST) Therapeutics under Development by Companies
Gastrointestinal Stromal Tumor (GIST) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Gastrointestinal Stromal Tumor (GIST) Therapeutics – Products under Development by Companies
Gastrointestinal Stromal Tumor (GIST) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Gastrointestinal Stromal Tumor (GIST) Therapeutics Development
Biogen Idec Inc.
Amgen Inc.
AstraZeneca PLC
Novartis AG
ImClone Systems Incorporated
SuperGen, Inc.
Bayer AG
Keryx Biopharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc.
Synta Pharmaceuticals Corp.
Ambit Biosciences Corporation
Deciphera Pharmaceuticals, LLC
AB Science
Gastrointestinal Stromal Tumor (GIST) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Motesanib - Drug Profile
Regorafenib - Drug Profile
IMC-3G33 - Drug Profile
Recentin - Drug Profile
BIIB021 - Drug Profile
AT13387 - Drug Profile
Ganetespib - Drug Profile
AC220 - Drug Profile
Gleevec - Drug Profile
ARO-002 - Drug Profile
Yondelis - Drug Profile
Trabectedin - Drug Profile
Doxorubicin + Flavopiridol - Drug Profile
Regorafenib - Drug Profile
SU011248 - Drug Profile
Imatinib Mesylate - Drug Profile
Glivec - Drug Profile
Sorafenib - Drug Profile
FOLFOX + Bevacizumab - Drug Profile
Mixed Bacterial Vaccine - Drug Profile
Imatinib Mesylate - Drug Profile
Imatinib - Drug Profile
Dasatinib - Drug Profile
Glivec - Drug Profile
Perifosine + Imatinib Mesylate - Drug Profile
AB1010 - Drug Profile
Perifosine + Sunitinib Malate - Drug Profile
Brostallicin - Drug Profile
Gleevec - Drug Profile
AUY922 - Drug Profile
Glivec - Drug Profile
Gleevec - Drug Profile
Temsirolimus - Drug Profile
Bevacizumab + Capecitabine + Carboplatin - Drug Profile
DP-3407 - Drug Profile
DP-3429 - Drug Profile
Dasatinib - Drug Profile
Gleevec - Drug Profile
Bevacizumab + Imatinib mesylate - Drug Profile
Imatinib Mesylate + SU011248 - Drug Profile
Glivec - Drug Profile
Glivec - Drug Profile
TH-302 + Sunitinib - Drug Profile
Gleevec + Nilotinib - Drug Profile
GDC-0449 + RO4929097 - Drug Profile
Imatinib Mesylate - Drug Profile
Bevacizumab + Dasatinib - Drug Profile
Telomerase Peptide + GM-CSF - Drug Profile
Nilotinib + Imatinib - Drug Profile
Alemtuzumab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisolone + Vincristine Sulfate - Drug Profile
Bevacizumab + 5-fluorouracil + Leucovorin + Oxaliplatin - Drug Profile
DCC-2618 - Drug Profile
Pazopanib - Drug Profile
CHP-MAGE-A4 Cancer Vaccine - Drug Profile
AT13387 + Imatinib - Drug Profile
HER2 B Cell Peptide Vaccine - Drug Profile
Sunitinib - Drug Profile
Gastrointestinal Stromal Tumor (GIST) Therapeutics – Drug Profile Updates
Gastrointestinal Stromal Tumor (GIST) Therapeutics – Discontinued Products
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Dormant Products
Gastrointestinal Stromal Tumor (GIST) – Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer 

List of Table

List of Tables
Number of Products Under Development for Gastrointestinal Stromal Tumor (GIST), H1 2013 9
Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Development by Companies, H1 2013 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Comparative Analysis by Late Stage Development, H1 2013 15
Comparative Analysis by Mid Clinical Stage Development, H1 2013 16
Comparative Analysis by Early Clinical Stage Development, H1 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 18
Products under Development by Companies, H1 2013 19
Products under Development by Companies, H1 2013 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2013 21
AstraZeneca PLC, H1 2013 22
Eli Lilly and Company, H1 2013 23
Plexxikon Inc., H1 2013 24
Novartis AG, H1 2013 25
SuperGen, Inc., H1 2013 26
Bayer AG, H1 2013 27
AEterna Zentaris Inc., H1 2013 28
Threshold Pharmaceuticals, Inc., H1 2013 29
Synta Pharmaceuticals Corp., H1 2013 30
Chipscreen Biosciences Ltd, H1 2013 31
Ambit Biosciences Corporation, H1 2013 32
Deciphera Pharmaceuticals, LLC, H1 2013 33
AB Science, H1 2013 34
Clovis Oncology, Inc., H1 2013 35
EirGen Pharma Ltd., H1 2013 36
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Stage and Molecule Type, H1 2013 42
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Drug Profile Updates 81
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Discontinued Products 102
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Dormant Products 103
Gastrointestinal Stromal Tumor (GIST) Therapeutics - Dormant Products (Contd..1) 104

List of Chart

List of Figures
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2013 9
Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 14
Late Stage Products, H1 2013 15
Mid Clinical Stage Products, H1 2013 16
Early Clinical Stage Products, H1 2013 17
Discovery and Pre-Clinical Stage Products, H1 2013 18
Assessment by Monotherapy Products, H1 2013 37
Assessment by Combination Products, H1 2013 38
Assessment by Route of Administration, H1 2013 39
Assessment by Stage and Route of Administration, H1 2013 40
Assessment by Molecule Type, H1 2013 41
Assessment by Stage and Molecule Type, H1 2013 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *